Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocili
© NewsMage 2024. All rights are reserved
© NewsMage 2024. All rights are reserved